Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04262154 · ClinicalTrials.gov registry record · Phase 2
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
A Phase 2 study of Metastatic Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 8
- Study locations
NCT04262154: Active Phase 2 study of Metastatic Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04262154 is a Phase 2 study of Metastatic Prostate Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 28 participants, below the 186-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (85% lower). The trial reports 8 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04262154, a Phase 2 study of Metastatic Prostate Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study is to find out whether adding the study drug atezolizumab and stereotactic body radiotherapy (SBRT) to standard treatment with abiraterone acetate, prednisone, and Lupron® (leuprolide) is a safe and effective way to treat previously untreated metastatic prostate cancer, and to see whether the study treatment works better than the standard treatment.
Primary Outcome
Failure is defined as: biochemical failure, radiographic progression defined by PCWG3, or death from any cause.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Prednisone
- DRUG Abiraterone
- RADIATION Stereotactic Body Radiotherapy (SBRT)
- DRUG GnRH analog
Study Locations (8)
New York
- Memorial Sloan Kettering Cancer Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Columbia University - New York
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2020-03-03 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What the registry record for NCT04262154 still lists
NCT04262154 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 186-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Metastatic Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which Atezolizumab is the first listed.
NCT04262154 lists 8 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT04262154 about?
NCT04262154 is a clinical study titled "Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer". This study is to find out whether adding the study drug atezolizumab and stereotactic body radiotherapy (SBRT) to standard treatment with abiraterone acetate, prednisone, and Lupron® (leuprolide) is a safe and effective way to treat previously untreated metastatic prostate cancer, and to see whether...
What is the current status of trial NCT04262154?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2020-03-03. Estimated completion is 2026-09.
What conditions does trial NCT04262154 study?
This clinical trial studies the following conditions: Metastatic Prostate Cancer.
What interventions are being tested in trial NCT04262154?
The interventions under investigation include: Atezolizumab (DRUG), Prednisone (DRUG), Abiraterone (DRUG), Stereotactic Body Radiotherapy (SBRT) (RADIATION), GnRH analog (DRUG).
Who is sponsoring clinical trial NCT04262154?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04262154 being conducted?
This trial has 8 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04262154's enrollment target sits among peer trials
28 34th of 41 higher than 8 of 41 other Metastatic Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
RECRUITING · Phase 2
-
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
RECRUITING · Phase 2
-
A Study of Tarlatamab for People With Prostate Cancer
RECRUITING · Phase 2
-
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
RECRUITING · Phase 2
-
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
RECRUITING · Phase 2
-
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI